Technical Analysis for EXAS - Exact Sciences Corporation

Grade Last Price % Change Price Change
D 68.22 -1.36% -0.94
EXAS closed down 1.36 percent on Friday, September 29, 2023, on 1.24 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Multiple of Ten Bearish Other 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -1.36%
Gapped Up Strength -1.36%
Up 3 Days in a Row Strength -1.36%
Oversold Stochastic Weakness -1.36%
Slingshot Bearish Bearish Swing Setup 1.13%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 8 hours ago
Down 1% about 8 hours ago
60 Minute Opening Range Breakdown about 12 hours ago
10 DMA Resistance about 12 hours ago
2x Volume Pace about 12 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Exact Sciences Corporation Description

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.


Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Pancreatic Cancer Medical Test Colorectal Cancer Lab Testing Molecular Diagnostics Inflammatory Bowel Disease Polyp Cancer Screening Genzyme Mayo Clinic Diagnostic Gastroenterology

Is EXAS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 100.76
52 Week Low 29.285
Average Volume 1,398,529
200-Day Moving Average 74.04
50-Day Moving Average 82.08
20-Day Moving Average 74.78
10-Day Moving Average 69.75
Average True Range 2.49
RSI (14) 31.03
ADX 37.14
+DI 17.01
-DI 34.89
Chandelier Exit (Long, 3 ATRs) 78.25
Chandelier Exit (Short, 3 ATRs) 72.75
Upper Bollinger Bands 86.51
Lower Bollinger Band 63.04
Percent B (%b) 0.22
BandWidth 31.38
MACD Line -4.36
MACD Signal Line -3.93
MACD Histogram -0.4277
Fundamentals Value
Market Cap 10.26 Billion
Num Shares 150 Million
EPS -1.76
Price-to-Earnings (P/E) Ratio -38.70
Price-to-Sales 13.72
Price-to-Book 7.93
PEG Ratio -1.07
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 72.92
Resistance 3 (R3) 73.27 72.05 72.13
Resistance 2 (R2) 72.05 70.86 71.88 71.87
Resistance 1 (R1) 70.14 70.12 69.53 69.79 71.61
Pivot Point 68.92 68.92 68.62 68.75 68.92
Support 1 (S1) 67.01 67.73 66.40 66.66 64.83
Support 2 (S2) 65.79 66.99 65.62 64.57
Support 3 (S3) 63.88 65.79 64.31
Support 4 (S4) 63.53